US2017136057A1PendingUtilityA1

Ophthalmic compositions with improved dessication protection and retention

Assignee: NOVARTIS AGPriority: May 4, 2012Filed: Feb 1, 2017Published: May 18, 2017
Est. expiryMay 4, 2032(~5.8 yrs left)· nominal 20-yr term from priority
A61K 47/32A61K 47/36A61P 27/02A61P 27/04A61K 9/08A61K 9/0048A61K 47/10A61K 47/02A61K 47/26A61K 31/736A61K 31/728A61K 31/047
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Claims

exact text as granted — not AI-modified
1 : An ophthalmic composition comprising 0.1 to 0.2 w/v % galactomannan, 0.1 to 0.2 w/v % hyaluronic acid, and 1.0 to 2.0 w/v % cis-diol, and wherein said galactomannan is hydroxypropyl guar and said cis-diol is sorbitol. 
     
     
         2 : A composition according to  claim 1  comprising 0.17 to 0.18 w/v % hydroxypropyl guar, 0.13 to 0.17 w/v % sodium hyaluronate, and 1.4 w/v % sorbitol. 
     
     
         3 : A composition according to  claim 1  wherein said cis-diol is present at a concentration of about 1.4 w/v %. 
     
     
         4 : A composition according to  claim 1  wherein further comprising borate. 
     
     
         5 : A composition according to  claim 1  further comprising a demulcent selected from the group consisting of:
 glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, polyacrylic acid, and combinations thereof. 
 
     
     
         6 : A composition according to  claim 5  wherein said demulcent is polypropylene glycol or polyethylene glycol. 
     
     
         7 : A composition according to  claim 1  further comprising a pharmaceutically active compound. 
     
     
         8 : A method for treating ophthalmic disease which comprises administering to a subject in need of such treatment a composition according to  claim 1 . 
     
     
         9 : A method according to  claim 8 , wherein the ophthalmic disease is dry eye. 
     
     
         10 : A composition according to  claim 4 , wherein said boric acid is present at a concentration of 0.1 to 1.8 w/v %. 
     
     
         11 : A composition according to  claim 5 , wherein said demulcent is polyethylene glycol and propylene glycol. 
     
     
         12 : A composition according to  claim 11 , wherein said polyethylene glycol is present at a concentration of 0.4 w/v %. 
     
     
         13 : A composition according to  claim 11  wherein said propylene glycol is present at a concentration of 0.3 w/v % hyaluronic acid. 
     
     
         14 : A composition according to  claim 1  comprising 0.17 to 0.18 w/v % hydroxypropyl guar and 0.13 to 0.17 w/v % hyaluronic acid. 
     
     
         15 : A composition according to  claim 1  wherein the osmolality of said composition is 210-320 milliosmoles per kilogram (mOsm/kg). 
     
     
         16 : A composition according to  claim 1  wherein said composition has a pH of 6.5 to 8.

Join the waitlist — get patent alerts

Track US2017136057A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.